RARE
ウルトラジェニックス・ファーマシューティカル
RARE
ウルトラジェニックス・ファーマシューティカル
Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biopharmaceutical company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million.
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript